Twist Bioscience Corporation (NASDAQ:TWST – Get Free Report) insider Dennis Cho sold 14,205 shares of the company’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $89.75, for a total transaction of $1,274,898.75. Following the completion of the sale, the insider directly owned 105,141 shares of the company’s stock, valued at $9,436,404.75. This represents a 11.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Dennis Cho also recently made the following trade(s):
- On Monday, June 22nd, Dennis Cho sold 346 shares of Twist Bioscience stock. The shares were sold at an average price of $87.32, for a total transaction of $30,212.72.
- On Monday, June 8th, Dennis Cho sold 402 shares of Twist Bioscience stock. The shares were sold at an average price of $69.84, for a total value of $28,075.68.
Twist Bioscience Trading Up 3.3%
Twist Bioscience stock traded up $3.19 during mid-day trading on Friday, hitting $99.84. The company’s stock had a trading volume of 4,274,502 shares, compared to its average volume of 1,512,186. Twist Bioscience Corporation has a 1 year low of $23.30 and a 1 year high of $104.23. The stock’s fifty day moving average is $66.16 and its two-hundred day moving average is $51.10. The firm has a market capitalization of $6.22 billion, a PE ratio of -75.07 and a beta of 2.23. The company has a current ratio of 2.70, a quick ratio of 2.42 and a debt-to-equity ratio of 0.03.
Wall Street Analysts Forecast Growth
TWST has been the subject of several research analyst reports. Guggenheim raised their price target on Twist Bioscience from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. UBS Group set a $89.00 target price on shares of Twist Bioscience in a research note on Monday, June 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research note on Wednesday. Canaccord Genuity Group started coverage on Twist Bioscience in a research note on Monday, June 15th. They set a “buy” rating and a $90.00 target price for the company. Finally, Barclays boosted their price objective on Twist Bioscience from $65.00 to $95.00 and gave the stock an “overweight” rating in a research report on Wednesday. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Twist Bioscience has a consensus rating of “Moderate Buy” and an average target price of $74.60.
Check Out Our Latest Report on Twist Bioscience
Hedge Funds Weigh In On Twist Bioscience
Several large investors have recently bought and sold shares of TWST. ARK Investment Management LLC increased its position in Twist Bioscience by 12.4% during the fourth quarter. ARK Investment Management LLC now owns 7,559,495 shares of the company’s stock worth $239,787,000 after buying an additional 832,687 shares during the period. Artisan Partners Limited Partnership increased its stake in Twist Bioscience by 26.7% in the third quarter. Artisan Partners Limited Partnership now owns 6,410,900 shares of the company’s stock valued at $180,403,000 after purchasing an additional 1,349,867 shares during the period. William Blair Investment Management LLC increased its holdings in shares of Twist Bioscience by 43.7% in the fourth quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock valued at $188,874,000 after purchasing an additional 1,812,146 shares during the period. EdgePoint Investment Group Inc. lifted its stake in shares of Twist Bioscience by 31.7% in the 4th quarter. EdgePoint Investment Group Inc. now owns 5,377,991 shares of the company’s stock worth $170,590,000 after acquiring an additional 1,295,672 shares during the period. Finally, State Street Corp boosted its holdings in shares of Twist Bioscience by 17.4% in the fourth quarter. State Street Corp now owns 3,627,818 shares of the company’s stock valued at $115,074,000 after acquiring an additional 538,755 shares in the last quarter.
Twist Bioscience Company Profile
Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.
Featured Articles
- Five stocks we like better than Twist Bioscience
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
